On Friday, Resource America Inc (NASDAQ:REXI)’s shares declined -2.38% to $7.78.
Resource America, Inc. ( REXI) declared that its Board of Directors has authorized the Company to repurchase up to $25.0 million of its common stock. This repurchase authorization replaces the Company’s previous share repurchase authorization from September 2014, following which the Company has repurchased 864,641 shares of its common stock. Share repurchases may be made from time to time through open market purchases or privately negotiated transactions at the discretion of the Company and in accordance with the rules of the Securities and Exchange Commission, as applicable. The amount and timing of any repurchases will depend on market conditions and other factors.
Resource America, Inc. is an asset administration company that specializes in real estate and credit investments. The Company’s objective is to be best in class among asset managers in the real estate and credit sectors as measured by returns to investors and the quality of the funds and businesses it manages. Resource America’s investments emphasize compriseent value and long-term returns with an income orientation. For more information please visit our website at www.resourceamerica.com or contact Marketing and Investor Relations at [email protected].
Resource America, Inc. operates as an asset administration company. The company, through its auxiliaries, operates in three segments: Financial Fund Administration; Real Estate; and Equipment Finance. The Financial Fund Administration segment engages in the formation and collateral administration of structured financial products and of issuers of collateralized debt obligations, such as trust preferred securities, asset backed securities, leveraged loans, private equity, commercial mortgage backed securities, residential mortgage backed securities, collateralized debt obligations, and home equity loans.
ImmunoGen, Inc. (NASDAQ:IMGN)’s shares dropped -2.58% to $13.58.
ImmunoGen, Inc. ( IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, recently stated financial results for the Company’s 2015 fiscal year ended June 30, 2015. ImmunoGen also offered an update on product programs and guidance for its 2016 fiscal year.
Updates on Product Programs
Mirvetuximab soravtansine (IMGN853), a potential new therapy for many cases of ovarian cancer in addition to for other solid tumors that highly express folate receptor α (FRα); wholly owned by ImmunoGen.
- Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in May showed that treatment with mirvetuximab soravtansine monotherapy achieved marked tumor shrinkage in 53% of patients with FRα-positive platinum-resistant ovarian cancer in the expansion cohort of a Phase I trial. The enrollment of patients into this expansion cohort is predictable to complete by year end, with presentation of the findings for the full 40-patient cohort anticipated in mid-2016.
- ImmunoGen plans to initiate a Phase 2 trial assessing mirvetuximab soravtansine as a single agent for FRα-positive pre-treated ovarian cancer in late 2015; this trial potentially could support an accelerated registration pathway.
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates comprise IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia.
At the end of Friday’s trade, Dover Corp (NYSE:DOV)‘s shares dipped -0.62% to $63.95.
Dover (DOV) raised its quarterly cash dividend to $0.42 (forty-two cents) per share, from the previous $0.40 (forty cents) per share, an enhance of $0.02 (two cents) or 5%. This is the 60th successive year in which the Company has raised its annual cash dividend. With this enhance, Dover has the third longest record of successive annual dividend enhances of listed companies, as stated by Mergent`s Dividend Achievers.
This raised dividend will be paid on September 15, 2015 to shareholders of record as of August 31, 2015.
Dover Corporation manufactures and sells a range of equipment and components, specialty systems, and support services in the United States. The company operates in four segments: Energy, Engineered Systems, Fluids, and Refrigeration & Food Equipment. The Energy segment provides solutions and services for the production and processing of oil, natural gas liquids, and gas to drilling and production, bearings and compression, and automation end markets.
HSBC Holdings plc (ADR) (NYSE:HSBC), ended its Friday’s trading session with 0.02% gain, and closed at $43.78.
HSBC Bank USA, N.A. (HSBC) has depended on the support of its customers, shareholders and employees throughout its history. To mark the 150th anniversary HSBC wants to say ‘thank you’, by making a US$150m fund accessible to community projects and local charities over three years (2015-2017).
More than 50,000 HSBC employees voted on charitable themes in 2014. There were three clear winners: young people and their education; medical welfare and research; and the environment and wildlife.
HSBC’s regional administration teams have carefully selected over 140 charities worldwide to benefit from the funding. Each organization will provide a positive and sustainable change in their area of focus. The selection of charities is based on employee votes by region.
HSBC Holdings plc provides banking and financial products and services. It operates through four businesses Retail Banking and Wealth Administration, Commercial Banking, Global Banking and Markets, and Global Private Banking. The company’s Retail Banking and Wealth Administration business offers a range of personal banking products and services, counting current and savings accounts, mortgages and personal loans, credit cards, debit cards, and local and international payment services; and wealth administration services comprising insurance and investment products, asset administration services, and financial planning services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
